PT  - JOURNAL ARTICLE
AU  - Julien Kirchgesner
AU  - Rishi J Desai
AU  - Maria C Schneeweiss
AU  - Laurent Beaugerie
AU  - Sebastian Schneeweiss
AU  - Seoyoung C Kim
TI  - Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn’s disease
AID  - 10.1136/gutjnl-2022-327002
DP  - 2022 Sep 01
TA  - Gut
PG  - 1781--1789
VI  - 71
IP  - 9
4099  - http://gut.bmj.com/content/71/9/1781.short
4100  - http://gut.bmj.com/content/71/9/1781.full
SO  - Gut2022 Sep 01; 71
AB  - Objective While infliximab combined to thiopurines is more effective than infliximab monotherapy in patients with Crohn’s disease (CD) and UC, the impact of adding thiopurines to vedolizumab remains controversial. We emulated two target trials comparing the effectiveness of combination therapy versus vedolizumab monotherapy in CD and UC.Design Based on two US and the French nationwide healthcare databases, patients with CD and UC who initiated vedolizumab were identified. The study methodology, including confounding adjustment and outcome definitions, were previously validated in successful emulations of the SONIC and SUCCESS trials. Risk ratios for treatment failure based on hospitalisation or surgery related to disease activity, treatment switch, or prolonged corticosteroids use, were estimated after 1:1 propensity score (PS) matching.Results Among a total of 10 299 vedolizumab users, 804 CD and 1088 UC pairs of combination therapy versus vedolizumab monotherapy users were PS matched. Treatment failure occurred at week 26 in 236 (29.3%) and 376 (34.3%) patients with CD and at week 16 in 236 (21.7%) and 263 (24.2%) patients with UC initiating combination therapy and vedolizumab monotherapy, respectively. The risk of treatment failure was decreased with combination therapy compared with vedolizumab monotherapy in CD (RR 0.85, 95% CI: 0.74 to 0.98) and to a lesser extent in UC (RR 0.90, 95% CI: 0.77 to 1.05). Findings were consistent across databases.Conclusion Using validated methodologies, combination therapy with vedolizumab and thiopurines was associated with lower treatment failure compared with vedolizumab monotherapy in CD but not UC across the USA and France.All data relevant to the study are included in the article or uploaded as supplementary information. Not applicable.